HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Q0179 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 8 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1991 | Apr 1, 1998 | Dec 31, 2011 | No Longer Used | |
J8650 | Nabilone | Cesamet | 1 mg | Ancillary Therapy | Antiemetic | Cannabinoid | Yes | 1985 | Jan 1, 2007 | In Use | ||
J1626 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 100 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1993 | Jan 1, 2009 | In Use | ||
C9448 | Netupitant/Palonosetron | Akynzeo | 300mg/0.5 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Yes | 2014 | Apr 1, 2015 | Jun 30, 2015 | No Longer Used | |
NA | Aprepitant | Emend | 40 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 10 mg | Ancillary Therapy | Chemoprotective | Antidote | Yes | 1952 | Jan 1, 1997 | In Use | ||
S0091 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 1 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1993 | Jan 1, 2002 | In Use | ||
Q0167 | Dronabinol | Marinol | 2.5 mg | Ancillary Therapy | Antiemetic | CB1/CB2 | Yes | 1985 | Apr 1, 1998 | In Use | ||
NA | Aprepitant | Emend | 80 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
J1440 | Filgrastim | Neupogen, Zarxio | 300 mcg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 1991 | Jan 1, 2014 | Dec 31, 2013 | No Longer Used | |
Nirogacestat | Ogsiveo | 50mg, 100mg, 150mg | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Yes | 2023 | In Use | ||||
Q9978 | Netupitant/palonostron | Akynzeo | 300mg/0.5 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Yes | 2014 | Jul 1, 2015 | Dec 31, 2015 | No Longer Used | |
J0640 | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 50 mg | Ancillary Therapy | Chemoprotective | Antidote | No | 1952 | Jan 1, 1997 | In Use | ||
J2430 | Pamidronate disodium | Aredia | 30mg | Ancillary Therapy | Bisphosphonate | No | 1987 | In Use | ||||
Q0166 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 1 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1993 | Jan 1, 2009 | In Use | ||
J2277 | Motixafortide | Motixafortide | 0.25mg | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | No | 2023 | Apr 17, 2024 | In Use | ||
Q5111 | Pegfilgrastim-cbqv | Udenyca | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2019 | Jan 1, 2019 | In Use | ||
NA | Ribociclib and letrozole | Kisqali Femara Co-pack | 200 mg/ 2.5 mg | Chemotherapy, Hormonal Therapy | Cyclin dependent kinase inhibitor/ aromatase inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
J9180 | Epirubicin | Epirubicin | 50 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1999 | Jan 1, 2001 | Dec 31, 2003 | No Longer Used | |
J9051 | Bortezomib (Maia) | Bortezomib | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | Yes | 2022 | Aug 28, 2023 | In Use | ||
NA | Crizotinib | Xalkori | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
J9297 | Pemetrexed (Sandoz) | Pemetrexed (Sandoz) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Mar 17, 2023 | In Use | ||
NA | Erdafitinib | Balversa | 3mg, 4mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Yes | 2019 | In Use | |||
C9424 | Daunorubicin | Daunorubicin Hydrochloride | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1996 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
NA | Ponatinib | Iclusig | 45 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.